Beta Sheet

A beta sheet forms when peptide chains run alongside one another in a nearly extended conformation and hydrogen-bond between strands rather than within a strand as a helix does. Each residue advances roughly 3.3 to 3.5 angstroms, so a strand covers more than twice the distance per residue a helix covers. Strands may run parallel or antiparallel, and the alternating pleat leaves successive side chains pointing to opposite faces, letting one face be hydrophobic and the other polar.

For peptide products the sheet is usually a liability rather than a feature. Amyloid fibrils are built from a cross-beta arrangement in which strands stack perpendicular to the fibril axis, and several therapeutic peptides adopt it under stress. Insulin fibrillates under heat and agitation, and human amylin is so aggregation-prone that its analogue pramlintide was made by substituting three prolines, residues that cannot fit a sheet, to block the transition.

The consequence is that beta-sheet propensity dictates how a formulation is handled and tested. Aggregation nucleates at air-liquid and liquid-solid interfaces, so shaking, foaming, repeated freeze-thaw and adsorption to a container all accelerate it, and surfactants are added precisely to occupy those interfaces. Aggregated material is also the main structural driver of immunogenicity, making this a safety question rather than only a potency one.

The error to avoid is reading clarity as absence of aggregation. Fibrils and oligomers become visible well after they form, so a solution that looks clean against a light box can carry a substantial subvisible particle burden; visual inspection is a release test for gross defects, not a stability assay. A vial that has been shaken rather than swirled may be compromised in a way its appearance never reveals.